#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|


#Text=[0029] Further, the solution method of the instant invention operates in a "signal-on" mode in which the presence of target DNA results in the increment of the signal.
1-1	0-1	[	_	
1-2	1-5	0029	_	
1-3	5-6	]	_	
1-4	7-14	Further	_	
1-5	14-15	,	_	
1-6	16-19	the	_	
1-7	20-28	solution	_	
1-8	29-35	method	_	
1-9	36-38	of	_	
1-10	39-42	the	_	
1-11	43-50	instant	_	
1-12	51-60	invention	_	
1-13	61-69	operates	_	
1-14	70-72	in	_	
1-15	73-74	a	_	
1-16	75-76	"	_	
1-17	76-85	signal-on	_	
1-18	85-86	"	_	
1-19	87-91	mode	_	
1-20	92-94	in	_	
1-21	95-100	which	_	
1-22	101-104	the	_	
1-23	105-113	presence	_	
1-24	114-116	of	_	
1-25	117-123	target	_	
1-26	124-127	DNA	_	
1-27	128-135	results	_	
1-28	136-138	in	_	
1-29	139-142	the	_	
1-30	143-152	increment	_	
1-31	153-155	of	_	
1-32	156-159	the	_	
1-33	160-166	signal	_	
1-34	166-167	.	_	

#Text=Therefore, it is unlikely that any factor other than the presence of target DNA would lead to the appearance or enhancement of the specific electrochemical signal.
#Text=[0030] For the detection and/or quantification of nucleic acid amplification product is performed in real time during the PCR reaction, it is important to note that the method and system according to this invention are thermally stable, having a negligible inhibitory effect on the PCR reaction.
2-1	168-177	Therefore	_	
2-2	177-178	,	_	
2-3	179-181	it	_	
2-4	182-184	is	_	
2-5	185-193	unlikely	_	
2-6	194-198	that	_	
2-7	199-202	any	_	
2-8	203-209	factor	_	
2-9	210-215	other	_	
2-10	216-220	than	_	
2-11	221-224	the	_	
2-12	225-233	presence	_	
2-13	234-236	of	_	
2-14	237-243	target	_	
2-15	244-247	DNA	_	
2-16	248-253	would	_	
2-17	254-258	lead	_	
2-18	259-261	to	_	
2-19	262-265	the	_	
2-20	266-276	appearance	_	
2-21	277-279	or	_	
2-22	280-291	enhancement	_	
2-23	292-294	of	_	
2-24	295-298	the	_	
2-25	299-307	specific	_	
2-26	308-323	electrochemical	_	
2-27	324-330	signal	_	
2-28	330-331	.	_	
2-29	332-333	[	_	
2-30	333-337	0030	_	
2-31	337-338	]	_	
2-32	339-342	For	_	
2-33	343-346	the	_	
2-34	347-356	detection	_	
2-35	357-360	and	_	
2-36	360-361	/	_	
2-37	361-363	or	_	
2-38	364-378	quantification	_	
2-39	379-381	of	_	
2-40	382-389	nucleic	_	
2-41	390-394	acid	_	
2-42	395-408	amplification	_	
2-43	409-416	product	_	
2-44	417-419	is	_	
2-45	420-429	performed	_	
2-46	430-432	in	_	
2-47	433-437	real	_	
2-48	438-442	time	_	
2-49	443-449	during	_	
2-50	450-453	the	_	
2-51	454-457	PCR	_	
2-52	458-466	reaction	_	
2-53	466-467	,	_	
2-54	468-470	it	_	
2-55	471-473	is	_	
2-56	474-483	important	_	
2-57	484-486	to	_	
2-58	487-491	note	_	
2-59	492-496	that	_	
2-60	497-500	the	_	
2-61	501-507	method	_	
2-62	508-511	and	_	
2-63	512-518	system	_	
2-64	519-528	according	_	
2-65	529-531	to	_	
2-66	532-536	this	_	
2-67	537-546	invention	_	
2-68	547-550	are	_	
2-69	551-560	thermally	_	
2-70	561-567	stable	_	
2-71	567-568	,	_	
2-72	569-575	having	_	
2-73	576-577	a	_	
2-74	578-588	negligible	_	
2-75	589-599	inhibitory	_	
2-76	600-606	effect	_	
2-77	607-609	on	_	
2-78	610-613	the	_	
2-79	614-617	PCR	_	
2-80	618-626	reaction	_	
2-81	626-627	.	_	

#Text=Also, this method is accurate, reproducible, and safe, even in the absence of an additional step of washing off of unreacted molecules, especially the soluble and non-incorporated labeled molecules and markers employed in the reaction.
#Text=[0031] When compared to optically-based devices, the present invention provides a technology that results in significantly reduced expenses; more particularly, this method may be employed in miniaturized devices, e.g. a portable real time PCR analyzer, which is currently unavailable in the market place.
#Text=[0032] FIG. 1 shows a scheme of a solid-phase method employing a red-ox probe according to one embodiment of the present invention.
#Text=[0033] FIG. 2A provides a graph showing differential pulse signals of ferrocene at different PCR cycle numbers according to the same embodiment of the present invention.
3-1	628-632	Also	_	
3-2	632-633	,	_	
3-3	634-638	this	*[1]	
3-4	639-645	method	*[1]	
3-5	646-648	is	_	
3-6	649-657	accurate	_	
3-7	657-658	,	_	
3-8	659-671	reproducible	_	
3-9	671-672	,	_	
3-10	673-676	and	_	
3-11	677-681	safe	_	
3-12	681-682	,	_	
3-13	683-687	even	_	
3-14	688-690	in	_	
3-15	691-694	the	_	
3-16	695-702	absence	_	
3-17	703-705	of	_	
3-18	706-708	an	_	
3-19	709-719	additional	_	
3-20	720-724	step	_	
3-21	725-727	of	_	
3-22	728-735	washing	_	
3-23	736-739	off	_	
3-24	740-742	of	_	
3-25	743-752	unreacted	_	
3-26	753-762	molecules	_	
3-27	762-763	,	_	
3-28	764-774	especially	_	
3-29	775-778	the	_	
3-30	779-786	soluble	_	
3-31	787-790	and	_	
3-32	791-807	non-incorporated	_	
3-33	808-815	labeled	_	
3-34	816-825	molecules	_	
3-35	826-829	and	_	
3-36	830-837	markers	_	
3-37	838-846	employed	_	
3-38	847-849	in	_	
3-39	850-853	the	_	
3-40	854-862	reaction	_	
3-41	862-863	.	_	
3-42	864-865	[	_	
3-43	865-869	0031	_	
3-44	869-870	]	_	
3-45	871-875	When	_	
3-46	876-884	compared	_	
3-47	885-887	to	_	
3-48	888-903	optically-based	_	
3-49	904-911	devices	_	
3-50	911-912	,	_	
3-51	913-916	the	_	
3-52	917-924	present	_	
3-53	925-934	invention	_	
3-54	935-943	provides	_	
3-55	944-945	a	_	
3-56	946-956	technology	_	
3-57	957-961	that	_	
3-58	962-969	results	_	
3-59	970-972	in	_	
3-60	973-986	significantly	_	
3-61	987-994	reduced	_	
3-62	995-1003	expenses	_	
3-63	1003-1004	;	_	
3-64	1005-1009	more	_	
3-65	1010-1022	particularly	_	
3-66	1022-1023	,	_	
3-67	1024-1028	this	_	
3-68	1029-1035	method	_	
3-69	1036-1039	may	_	
3-70	1040-1042	be	_	
3-71	1043-1051	employed	_	
3-72	1052-1054	in	_	
3-73	1055-1067	miniaturized	_	
3-74	1068-1075	devices	_	
3-75	1075-1076	,	_	
3-76	1077-1080	e.g	_	
3-77	1080-1081	.	_	
3-78	1082-1083	a	_	
3-79	1084-1092	portable	_	
3-80	1093-1097	real	_	
3-81	1098-1102	time	_	
3-82	1103-1106	PCR	_	
3-83	1107-1115	analyzer	_	
3-84	1115-1116	,	_	
3-85	1117-1122	which	_	
3-86	1123-1125	is	_	
3-87	1126-1135	currently	_	
3-88	1136-1147	unavailable	_	
3-89	1148-1150	in	_	
3-90	1151-1154	the	_	
3-91	1155-1161	market	_	
3-92	1162-1167	place	_	
3-93	1167-1168	.	_	
3-94	1169-1170	[	_	
3-95	1170-1174	0032	_	
3-96	1174-1175	]	_	
3-97	1176-1179	FIG	_	
3-98	1179-1180	.	_	
3-99	1181-1182	1	_	
3-100	1183-1188	shows	_	
3-101	1189-1190	a	_	
3-102	1191-1197	scheme	_	
3-103	1198-1200	of	_	
3-104	1201-1202	a	_	
3-105	1203-1214	solid-phase	_	
3-106	1215-1221	method	_	
3-107	1222-1231	employing	_	
3-108	1232-1233	a	_	
3-109	1234-1240	red-ox	_	
3-110	1241-1246	probe	_	
3-111	1247-1256	according	_	
3-112	1257-1259	to	_	
3-113	1260-1263	one	_	
3-114	1264-1274	embodiment	_	
3-115	1275-1277	of	_	
3-116	1278-1281	the	_	
3-117	1282-1289	present	_	
3-118	1290-1299	invention	_	
3-119	1299-1300	.	_	
3-120	1301-1302	[	_	
3-121	1302-1306	0033	_	
3-122	1306-1307	]	_	
3-123	1308-1311	FIG	_	
3-124	1311-1312	.	_	
3-125	1313-1315	2A	_	
3-126	1316-1324	provides	_	
3-127	1325-1326	a	_	
3-128	1327-1332	graph	_	
3-129	1333-1340	showing	_	
3-130	1341-1353	differential	_	
3-131	1354-1359	pulse	_	
3-132	1360-1367	signals	_	
3-133	1368-1370	of	_	
3-134	1371-1380	ferrocene	_	
3-135	1381-1383	at	_	
3-136	1384-1393	different	_	
3-137	1394-1397	PCR	_	
3-138	1398-1403	cycle	_	
3-139	1404-1411	numbers	_	
3-140	1412-1421	according	_	
3-141	1422-1424	to	_	
3-142	1425-1428	the	_	
3-143	1429-1433	same	_	
3-144	1434-1444	embodiment	_	
3-145	1445-1447	of	_	
3-146	1448-1451	the	_	
3-147	1452-1459	present	_	
3-148	1460-1469	invention	_	
3-149	1469-1470	.	_	
